Search Results

You are looking at 1 - 10 of 10 items for :

  • "tamoxifen metabolism" x
Clear All
Full access

Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes and Vered Stearns

Pharmacol Exp Ther 2006 ; 318 : 503 – 512 . 9 Borges S Desta Z Li L . Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment . Clin Pharmacol Ther 2006 ; 80 : 61

Full access

Kostandinos Sideras and Charles L. Loprinzi

these drugs. Medications for Hot Flashes That Might Inhibit Tamoxifen Metabolism Several medications are strong inhibitors of CY-P2D6, and some have been shown to interfere with tamoxifen metabolism ( Table 2 ). From the medications discussed

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro and John H. Ward

Certain CYP2D6 genotypes have also been reported to be markers of poor tamoxifen metabolism. 82 , 83 Nevertheless, the consensus of the panel is that further validation of this biomarker is needed before it can be used to select patients for tamoxifen

Full access

Therese B. Bevers, John H. Ward, Banu K. Arun, Graham A. Colditz, Kenneth H. Cowan, Mary B. Daly, Judy E. Garber, Mary L. Gemignani, William J. Gradishar, Judith A. Jordan, Larissa A. Korde, Nicole Kounalakis, Helen Krontiras, Shicha Kumar, Allison Kurian, Christine Laronga, Rachel M. Layman, Loretta S. Loftus, Martin C. Mahoney, Sofia D. Merajver, Ingrid M. Meszoely, Joanne Mortimer, Lisa Newman, Elizabeth Pritchard, Sandhya Pruthi, Victoria Seewaldt, Michelle C. Specht, Kala Visvanathan, Anne Wallace, Mary Ann Bergman and Rashmi Kumar

Citalopram and venlafaxine do not disrupt tamoxifen metabolism. Certain CYP2D6 genotypes have been reported to be markers of poor tamoxifen metabolism. 145 , 146 Nevertheless, the consensus of the NCCN Breast Cancer Risk Reduction Panel is that further

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

2000 ; 356 : 2059 – 2063 . 201 Garber K . Tamoxifen pharmacogenetics moves closer to reality . J Natl Cancer Inst 2005 ; 97 : 412 – 413 . 202 Jin Y Desta Z Stearns V . CYP2D6 genotype, antidepressant use, and tamoxifen

Full access

Robert Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Craig D. Blinderman, Barry Boston, Charles Cleeland, Nessa Coyle, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Nora A. Janjan, Sloan Beth Karver, Michael H. Levy, Maureen Lynch, Natalie Moryl, Barbara A. Murphy, Suzanne A. Nesbit, Linda Oakes, Eugenie A. Obbens, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan Urba and Sharon M. Weinstein

, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst 2005 ; 97 : 30 – 39 . 58. Manfredi PL Gonzales GR Sady R . Neuropathic pain in patients with cancer . J Palliat Care 2003 ; 19 : 115 – 118

Full access

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead and Rashmi Kumar

inhibiting a particular isoform of CYP2D6. However, the mild CYP2D6 inhibitors, such as citalopram, escitalopram, sertraline, and venlafaxine, seem to have no or only minimal effect on tamoxifen metabolism. 236 , 305 , 306 Follow-up also includes assessment

Full access

Robert A. Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Sorin Buga, Charles Cleeland, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Mark Green, Nora A. Janjan, Mihir M. Kamdar, Michael H. Levy, Maureen Lynch, Rachel M. McDowell, Natalie Moryl, Suzanne A. Nesbit, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan G. Urba, Sharon M. Weinstein, Mary Dwyer and Rashmi Kumar

Desta Z Stearns V . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst 2005 ; 97 : 30 – 39 . 124. Johannessen Landmark C . Antiepileptic drugs in non

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

, fluvoxamine, gabapentin, sertraline, and venlafaxine seem to have no or only minimal effect on tamoxifen metabolism. 206 , 264 If an aromatase inhibitor is considered in women with amenorrhea after treatment, baseline levels of estradiol and gonadotropin

Full access

Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles Cleeland, David Craig, Ellin Gafford, Heather Greenlee, Eric Hansen, Arif H. Kamal, Mihir M. Kamdar, Susan LeGrand, Sean Mackey, M. Rachel McDowell, Natalie Moryl, Lisle M. Nabell, Suzanne Nesbit, BCPS, Nina O’Connor, Michael W. Rabow, Elizabeth Rickerson, Rebecca Shatsky, Jill Sindt, Susan G. Urba, Jeanie M. Youngwerth, Lydia J. Hammond and Lisa A. Gurski

: 581 – 590 e581 . 10.1016/j.jpainsymman.2012.10.230 36. Jin Y , Desta Z , Stearns V , . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst 2005 ; 97 : 30 – 39